内容目录 http://www.huajinsc.cn/ （一）转债分析 | --- | --- | --- | --- | --- | |-------|---------------------------|----------------------------------------------|--------------|---------------------| | 序号 | | 项目名称 | 项目投资总额 | 拟使用募集资金 金额 | | 1 | | 智慧医疗物联网云平台升级项目 | 5,026.63 | 4,903.22 | | | | 光谷人民医院医疗专项设计施工总承包项目 | 16,983.96 | 14,000.00 | | 2 | 洁净医疗专项工程 建设项目 | 上海交通大学医学院浦东校区工程(标段二)科研集 | | | | | | 群工艺增加(安装+装饰装修工程 ) 专业分包工程 | 16,024.83 | 14,000.00 | | 3 | | 洁净医疗配套产品生产基地建设项目 | 13,189.94 | 11,051.54 | | | 耗材物流仓储配送 | 鄂西分仓 | 5, ...

证券时报e公司讯，华康医疗在机构调研时表示，前期受多种因素影响，订单具有一定的滞后性，今年 订单呈现明显增长趋势，截至10月底，公司新增了20亿订单，其中医疗净化工程规模占比80-90%。 市场地区方面：传统的浙江等地区一直保持良好态势，今年重庆、云南、江西的订单明显增加，这些区 域的订单超过了湖北的订单，说明公司全面铺开的营销策略已经见效。 ...

编号：2024-005 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for the third quarter was RMB 525.7 million, a 16.28% increase year-over-year[3] - Net profit attributable to shareholders was RMB 30.4 million, a 17.13% decrease year-over-year[3] - Operating revenue for the period was 1,079,614,618.16 yuan, down from 1,145,105,818.00 yuan in the same period last year[17] - Operating costs for the period were 1,010,799,535.25 yuan, a decrease from 1,065,544,396.60 yuan in the previous year[17] - Net profit attributable to the parent company's shareholders was 19,635,357.61 RMB, with a minority shareholder loss of -112,859.07 RMB[18] - Basic and diluted earnings per share were both 0.19 RMB[19] Cash Flow - Operating cash flow for the first nine months was negative RMB 115.7 million, a 61.57% improvement year-over-year[8] - Investment cash flow for the first nine months was negative RMB 122.6 million, a 973.97% decrease year-over-year due to increased investment in the Yungu project and office building renovations[8] - Financing cash flow for the first nine months was RMB 183.1 million, a 47.26% decrease year-over-year due to increased repayment of bank loans and interest[8] - Cash flow from operating activities was -115,709,862.52 RMB, a significant improvement from -301,092,562.46 RMB in the previous period[21] - Cash flow from investing activities was -122,647,252.56 RMB, compared to 14,033,386.17 RMB in the previous period[21] - Cash flow from financing activities was 183,121,584.63 RMB, a decrease from 347,238,234.56 RMB in the previous period[21] - The company received 595,000,000.00 RMB from borrowings, an increase from 391,000,000.00 RMB in the previous period[21] - The company repaid 393,000,000.00 RMB in debt, significantly higher than the 20,000,000.00 RMB repaid in the previous period[21] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 3.19 billion, a 10.43% increase compared to the end of the previous year[3] - Total assets increased to 3,192,001,663.99 yuan, up from 2,890,469,587.02 yuan at the beginning of the period[15] - Total liabilities rose to 1,409,815,382.82 yuan, compared to 1,136,553,310.20 yuan at the start of the period[16] - Owner's equity grew to 1,782,186,281.17 yuan, up from 1,753,916,276.82 yuan at the beginning of the period[16] - Accounts receivable rose to 1,522,130,715.44 yuan, up from 1,371,620,009.09 yuan at the beginning of the period[14] - Inventory increased to 411,299,368.38 yuan, up from 274,909,613.70 yuan at the start of the period[14] - Short-term borrowings stood at 440,000,000.00 yuan, up from 409,545,194.19 yuan at the beginning of the period[15] - The company's cash and cash equivalents at the end of the period were 117,312,982.00 RMB, down from 193,509,870.32 RMB at the beginning of the period[21] R&D and Investments - R&D expenditure capitalized increased by 77.15% to RMB 15.1 million[6] - R&D expenses for the period were 43,785,813.40 yuan, down from 62,295,379.04 yuan in the same period last year[17] - Investment cash flow for the first nine months was negative RMB 122.6 million, a 973.97% decrease year-over-year due to increased investment in the Yungu project and office building renovations[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 9,008[9] - Tan Pingtao holds 44.23% of the shares, totaling 46,708,990 shares[9] - Sunshine Life Insurance Co., Ltd. holds 6.31% of the shares, totaling 6,661,246 shares[9] - Wuhan Kanghui Investment Management Center holds 4.56% of the shares, totaling 4,815,360 shares[9] - Hu Xiaoyan holds 2.96% of the shares, totaling 3,123,650 shares[9] - Chongqing Jinpu Medical Health Service Industry Equity Investment Fund holds 1.63% of the shares, totaling 1,718,800 shares[9] - Wuxi Guolian Innovation Investment Co., Ltd. holds 1.00% of the shares, totaling 1,056,000 shares[9] - Tan Pingtao's restricted shares will be released on July 28, 2025, totaling 46,708,990 shares[12] - Wuhan Kanghui Investment Management Center's restricted shares will be released on July 28, 2025, totaling 4,815,360 shares[13] - Wuxi Guolian Innovation Investment Co., Ltd.'s restricted shares were released on February 8, 2024, totaling 1,056,000 shares[13] Financial Expenses - Financial expenses increased to 15,620,339.91 yuan, up from 3,186,970.40 yuan in the previous year[17] - Interest expenses increased to 15,271,644.44 RMB, while interest income decreased to 1,083,515.51 RMB[18] Other Financial Metrics - Accounts receivable impairment provision increased by 161.77% to RMB 54.8 million[7] - Prepaid expenses increased by 224.59% to RMB 59.6 million due to increased prepayments for project materials[6] - Inventory increased by 49.61% to RMB 411.3 million due to the expansion of medical purification system integration and laboratory projects[6] - The company's third-quarter report was unaudited[22]

华康医疗：预中标昆明市西山区人民医院迁建项目 财联社10月24日电，华康医疗公告，公司参与了"昆 明市西山区人民医院三级综合医院迁建项目-医疗专项净化工程设计施工一体化"项目的投标，并成为第 一中标候选人。 投标报价为设计部分下浮率26%，施工部分下浮率2.2%，工期为自合同签订生效之日起180日历天内完 成全部工作。 该项目的实施预计对公司未来经营业绩产生积极影响。 但目前该项目尚处于中标候选人公示阶段，公司尚未取得《中标通知书》，存在一定的不确定性。 查看公告原文 ...

武汉华康世纪医疗股份有限公司 2024 年半年度报告全文 武汉华康世纪医疗股份有限公司 2024 年半年度报告 2024-068 2024 年 8 月 30 日 1 武汉华康世纪医疗股份有限公司 2024 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人谭平涛、主管会计工作负责人张英超及会计机构负责人(会计 主管人员)张英超声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及未来计划或规划等前瞻性陈述，均不构成公司对投 资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 公司在本半年度报告中详细阐述了未来可能发生的有关风险因素及对策， 详见"第三节管理层讨论与分析"之"十、公司面临的风险和应对措施"， 敬请投资者予以关注。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 武汉华康世纪医疗股份有限公司 2024 年半年 ...

证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 编号：2024-004  特定对象调研 分析师会议 投资者关 □媒体采访 业绩说明会 系活动类 □新闻发布会 路演活动 别 现场参观  其他（电话会议） 参与单位 橡果资产 魏鑫 、高特佳投资 葛战一、金股证券投资 曹志平、华 名称及人 泰证券 邵凌、安卓投资 李伟、玖金(深圳)投资 郑奇国 员姓名 时间 2024年6 月4 日14:00-14:40 地点 线上 上市公司 接待人员 财务负责人张英超、证券事务代表李心怡 姓名 本次活动主要问题汇总如下： 1、公司如何应对医疗净化系统项目实施过程中可能出现的风 险？ 答：公司项目实施过程中主要风险是应收账款风险，主要应对 措施：①公司定期(或至少每年)对客户资信情况进行评估；逾期没 有回收的货款，加强回收力度，并保留收款记录。②加强项目管理， 通过加强供应商管理和内部管控，提高项目现场的管理水平，加快 项目实施进度；同时，公司通过加强对已完工项目的管理，加快已 投资者关 完工项目的结算工作，从而推动客户的审计结算程序，加快客户回 系活动主 款进度。 ...

编号：2024-003 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关 系活动类 别 | 特定对象调研 □媒体采访 □新 ...

编号：2024-002 证券代码：301235 证券简称：华康医疗 | --- | --- | --- | |-------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | 投资者关系 | ☐ 媒体采访 | ☐ 业绩说明会 | | 活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 其他（ 2024 | 年湖北辖区上市公司投资者网上集体接待日活动） | | 参与单位 | 线上参与" 2024 | 年湖北辖区上市公司投资者网上集体接待日活动" | | 名称及人 员姓名 | 的全体投资者 | | | 时间 | 2024年05月16 日 | 14:30-16:00 | | 地点 | 全景网"投资者关系互动平台"（ | https://ir.p5w.net ） | ...